From Alan Neal, Pathlab, NZ. Just wanted a private conversation about the January 11, 2018 Fritsma Factor entry, "POC and Plasma-Based PT/INRs." I do not agree with the comments made within this article and challenge the logic used. Essentially, if monitoring an enzymatic pathway such as coagulation, with the 'detector' being used is fibrinogen to fibrin, then that rate of reaction will be dependent on the substrate concentration, i. e., fibrinogen, and the sensitivity of the analyser to detect the end point. So if no or reduced fibrinogen or dysfibrinogen, then reduced Vmax and hence PT/INR will be more prolonged than test system using a clot based end point detection.
Posts - Global Hemostasis Assays
Jan 22, 2018 10:41am
Jan 12, 2017 11:55am
A colleague saw our January 10, 2017 entry describing T2MR, an emerging global hemostasis methodology, and responded with information about sonic estimation of elasticity via resonance (SEER) sonorheometry, a non-contact technology that employs ultrasound to measure whole blood parameters similar to the viscoelasticity data
Jan 10, 2017 2:11pm
You may be hearing about the emerging diagnostic nanotechnology, T2 Magnetic Resonance (T2MR). Here is a summary of this intriguing new methodology that promises to revolutionize hemostasis testing.